MOUNTAIN VIEW, Calif., May 11, 2021 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX) today reported financial results for the first quarter ended April 3, 2021.
First Quarter Highlights
- Closed strategic collaboration with Topcon Corporation netting $19.5 million in new funds
- Record first quarter revenue of $12.0 million, an increase of 33% from the $9.0 million in the prior year period
- 10% from new products acquired from Topcon
- Cyclo G6® product family revenue of $3.3 million, an increase of 15% year-over-year
- 13,600 Cyclo G6 probes sold, a 4% year-over-year increase despite continued COVID-19 impacts
- International sales of Cyclo G6 probes increased by 18%, setting a new quarterly record
- 64 Cyclo G6 Glaucoma Laser Systems sold, compared to 38 in the prior year period
- Retina product revenue grew 61% year-over-year to $6.7 million
- 16% from sales of PASCAL® products acquired from Topcon
- Cash at quarter-end of $28 million
- First new 810 Laser sold in March
- Showcased 810 Laser and PASCAL Synthesis™ at the 2021 Hawaiian Eye Meeting in May
“We enjoyed a strong start to 2021 and our positive momentum continued with revenue that exceeded pre-COVID levels, setting a record for first quarter revenue. During the quarter, we saw international adoption of our Cyclo G6 probes rebound strongly, leading to a new first quarter high in Cyclo G6 probe sales. Additionally, we saw strong performance in our retina business, which was further bolstered by the initial sales of PASCAL products acquired from Topcon,” said David I. Bruce, President and CEO of Iridex.
“The investments we made in our product portfolio over the past year and a half are really starting to pay off for the company, particularly with respect to our enhanced retina products. Our focus is now shifting to expand our sales and marketing programs, where we are broadening efforts to demonstrate the many benefits of our non-incisional glaucoma therapy. We intend to leverage our strengthened balance sheet following the Topcon transaction, and pursue the expanding global opportunities we see in both our glaucoma and retina product portfolios,” concluded Bruce.
First Quarter 2021 Financial ResultsRevenue for the three months ending April 3, 2021 increased 33% to $12.0 million from $9.0 million during the same period of the prior year. Excluding newly acquired PASCAL products, revenue increased 19% over the first quarter of 2020.
Gross profit for the first quarter of 2021 increased to $4.9 million, a 41% gross margin, compared to $3.9 million, a 43% gross margin, in the same period last year. The gross margin reduction was primarily attributable to a higher portion of revenue coming from wholesale capital equipment sales.
Operating expenses for the first quarter of 2021 increased 22% to $6.8 million compared to $5.6 million in the same period of the prior year, mainly due to additional expenses in PASCAL operations and non-recurring Topcon transaction and integration expenses.
Net Loss for the first quarter of 2021 was $2.0 million, compared to $1.7 million in the same period of the prior year. Net Loss on a per share basis was $0.14 versus $0.12 last year.
Cash usage in the first quarter was $1.1 million, including approximately $0.5 million of non-recurring Topcon transaction payments, which resulted in cash of $28 million at quarter-end.
Guidance for Full Year 2021 Iridex expects total revenue for fiscal year 2021 to be $48 million to $51 million, reflecting growth of 32% - 40% over fiscal year 2020. In addition, Cyclo G6 probe sales of 56,000 to 59,000 and Glaucoma Laser System sales of 250 to 275 are expected in 2021.
Webcast and Conference Call InformationIridex’s management team will host a conference call today beginning at 2:00 p.m. PT / 5:00 p.m. ET. Investors interested in listening to the conference call may do so by dialing (844) 707-0665 for domestic callers or (703) 326-3030 for international callers, using conference ID: 1282162. A live and archived webcast of the event will be available on the “Investors” section of the Company’s website: www.iridex.com.
About Iridex Iridex Corporation is a worldwide leader in developing, manufacturing, and marketing innovative and versatile laser-based medical systems, delivery devices and consumable instrumentation for the ophthalmology market. The Company’s proprietary MicroPulse® technology delivers a differentiated treatment that provides safe, effective, and proven treatment for targeted sight-threatening eye conditions. Iridex’s current product line is used for the treatment of glaucoma and diabetic macular edema (DME) and other retinal diseases. Iridex products are sold in the United States through a direct sales force and internationally primarily through a network of independent distributors into more than 100 countries. For further information, visit the Iridex website at www.iridex.com.
Safe Harbor StatementThis announcement contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Act of 1934, as amended, including those statements concerning the future momentum, demand and utilization of the Company's products, financial guidance, expected sales volumes and benefits from the Topcon partnership. These statements are not guarantees of future performance and actual results may differ materially from those described in these forward-looking statements as a result of a number of factors. Please see a detailed description of these and other risks contained in our Annual Report on Form 10-K for the fiscal year ended January 2, 2021, filed with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date and will not be updated.
Investor Relations ContactLeigh Salvo(415) 937-5404[email protected]
IRIDEX CorporationCondensed Consolidated Statements of Operations(In thousands, except per share data)(unaudited)
| Three Months Ended | ||||||||
| April 3, | March 28, | |||||||
| 2021 | 2020 | |||||||
| Total revenues | $ | 11,959 | $ | 9,021 | ||||
| Cost of revenues | 7,020 | 5,105 | ||||||
| Gross profit | 4,939 | 3,916 | ||||||
| Operating expenses: | ||||||||
| Research and development | 1,165 | 719 | ||||||
| Sales and marketing | 2,982 | 3,152 | ||||||
| General and administrative | 2,633 | 1,698 | ||||||
| Total operating expenses | 6,780 | 5,569 | ||||||
| Loss from operations | (1,841 | ) | (1,653 | ) | ||||
| Other (expense) income, net | (161 | ) | 9 | |||||
| Loss from operations before provision for income taxes | (2,002 | ) | (1,644 | ) | ||||
| Provision for income taxes | 8 | 7 | ||||||
| Net loss | $ | (2,010 | ) | $ | (1,651 | ) | ||
| Net loss per share: | ||||||||
| Basic | $ | (0.14 | ) | $ | (0.12 | ) | ||
| Diluted | $ | (0.14 | ) | $ | (0.12 | ) | ||
| Weighted average shares used in computing net loss per share | ||||||||
| Basic | 14,346 | 13,786 | ||||||
| Diluted | 14,346 | 13,786 | ||||||
IRIDEX CorporationCondensed Consolidated Balance Sheets(In thousands and unaudited)
| April 3, | January 2, | |||||||
| 2021 | 2021 | |||||||
| Assets | ||||||||
| Current assets: | ||||||||
| Cash and cash equivalents | $ | 27,993 | $ | 11,626 | ||||
| Accounts receivable, net | 8,185 | 7,289 | ||||||
| Inventories | 7,042 | 5,714 | ||||||
| Prepaid expenses and other current assets | 1,001 | 730 | ||||||
| Total current assets | 44,221 | 25,359 | ||||||
| Property and equipment, net | 719 | 449 | ||||||
| Intangible assets, net | 2,349 | 68 | ||||||
| Goodwill | 965 | 533 | ||||||
| Operating lease right-of-use assets, net | 1,228 | 1,428 | ||||||
| Other long-term assets | 77 | 132 | ||||||
| Total assets | $ | 49,559 | $ | 27,969 | ||||
| Liabilities and Stockholders' Equity | ||||||||
| Current liabilities: | ||||||||
| Accounts payable | $ | 1,687 | $ | 1,148 | ||||
| Accrued compensation | 1,873 | 1,965 | ||||||
| Accrued expenses | 1,447 | 990 | ||||||
| Other current liabilities | 2,274 | 816 | ||||||
| Current portion of PPP loan | 2,185 | 1,249 | ||||||
| Accrued warranty | 124 | 166 | ||||||
| Deferred revenue | 1,812 | 938 | ||||||
| Operating lease liabilities | 1,345 | 1,409 | ||||||
| Total current liabilities | 12,747 | 8,681 | ||||||
| Long-term liabilities: | ||||||||
| PPP loan | 312 | 1,248 | ||||||
| Accrued warranty | 81 | 81 | ||||||
| Deferred revenue | 10,653 | 289 | ||||||
| Operating lease liabilities | 95 | 282 | ||||||
| Other long-term liabilities | 22 | 22 | ||||||
| Total liabilities | 23,910 | 10,603 | ||||||
| Stockholders' equity: | ||||||||
| Common stock | 165 | 148 | ||||||
| Additional paid-in capital | 84,419 | 74,181 | ||||||
| Accumulated other comprehensive income (loss) | 19 | (19 | ) | |||||
| Accumulated deficit | (58,954 | ) | (56,944 | ) | ||||
| Total stockholders' equity | 25,649 | 17,366 | ||||||
| Total liabilities and stockholders' equity | $ | 49,559 | $ | 27,969 | ||||
